Ignacio Rodríguez-Izquierdo1, Chueca Natalia2, Federico García2, María de Los Ángeles Muñoz-Fernandez1,3. 1. Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón (HGUGM), Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish HIV-HGM BioBank, Madrid, Spain. 2. Servicio de Microbiología Hospital Universitario San Cecilio, Instituto de Investigación Sanitaria IBS, Granada Spain. 3. Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Madrid, Spain.
Abstract
Aim: Polyanionic carbosilane dendrimers have been shown to be safe and block human immunodeficiency virus type 1 (HIV-1) infection in a multifunctional manner. The aim of this study is to evaluate the appearance of HIV-1 resistance mutations after treatment with polyanionic carbosilane dendrimers. Materials & methods: A resistance mutation assay was performed on MT2 cells, viral quantity was measured by ELISA HIVp24gag and titration was carried out on TZM.bl. Next generation sequencing for HIV-1 Env was performed on G1-S4 or G2-S16 dendrimers supernatants. Results: Data showed the appearance of mutation resistance to G1-S4 treatment, inducing three significant mutations. G2-S16 did not generate any mutations and, furthermore, inhibited G1-S4-resistant viruses. Conclusion: G1-S4 treatment generates significant mutations in HIV-1NL4.3. G2-S16 does not generate resistance-associated mutation, suggesting that G2-S16 is safe as a HIV-entry inhibitor.
Aim: Polyanionic carbosilane dendrimers have been shown to be safe and block human immunodeficiency virus type 1 (HIV-1) infection in a multifunctional manner. The aim of this study is to evaluate the appearance of HIV-1 resistance mutations after treatment with polyanionic carbosilane dendrimers. Materials & methods: A resistance mutation assay was performed on MT2 cells, viral quantity was measured by ELISA HIVp24gag and titration was carried out on TZM.bl. Next generation sequencing for HIV-1Env was performed on G1-S4 or G2-S16 dendrimers supernatants. Results: Data showed the appearance of mutation resistance to G1-S4 treatment, inducing three significant mutations. G2-S16 did not generate any mutations and, furthermore, inhibited G1-S4-resistant viruses. Conclusion: G1-S4 treatment generates significant mutations in HIV-1NL4.3. G2-S16 does not generate resistance-associated mutation, suggesting that G2-S16 is safe as a HIV-entry inhibitor.
Authors: Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2022-01-12
Authors: I Relaño-Rodríguez; M S Espinar-Buitrago; V Martín-Cañadilla; R Gómez-Ramirez; J L Jiménez; M A Muñoz-Fernández Journal: J Nanobiotechnology Date: 2021-03-03 Impact factor: 10.435
Authors: I Rodríguez-Izquierdo; M J Serramía; R Gómez; G Espinosa; M Genebat; M Leal; M A Muñoz-Fernandez Journal: J Nanobiotechnology Date: 2022-03-21 Impact factor: 10.435
Authors: Alba Martin-Moreno; Rafael Ceña-Diez; María Jesús Serramía; José Luis Jiménez; Rafael Gómez-Ramírez; Mariángeles Muñoz-Fernández Journal: Int J Mol Sci Date: 2022-02-25 Impact factor: 5.923
Authors: E Royo-Rubio; I Rodríguez-Izquierdo; M Moreno-Domene; T Lozano-Cruz; F J de la Mata; R Gómez; M A Muñoz-Fernández; J L Jiménez Journal: J Nanobiotechnology Date: 2021-05-28 Impact factor: 10.435